Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb 23;61(3):e01714-16.
doi: 10.1128/AAC.01714-16. Print 2017 Mar.

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

M Pamela Griffin  1 , Anis A Khan  2 , Mark T Esser  2 , Kathryn Jensen  2 , Therese Takas  2 , Martin K Kankam  3 , Tonya Villafana  2 , Filip Dubovsky  2
Affiliations
Clinical Trial

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

M Pamela Griffin et al. Antimicrob Agents Chemother. .

Abstract

Prevention of respiratory syncytial virus (RSV) illness in infants is a major public health priority, but there is no approved vaccine. Palivizumab is a monoclonal antibody that provides RSV prophylaxis but requires 5 monthly injections and is approved only for infants who experience the greatest morbidity and mortality from RSV. Thus, there remains a significant unmet medical need for prevention of RSV disease in healthy infants. MEDI8897 is a recombinant human RSV monoclonal antibody with a modified Fc region that extends its half-life and is being developed as RSV prophylaxis for all infants. In this phase 1, first-in-human, placebo-controlled study, 136 healthy adults were randomized to receive a single dose of MEDI8897 (n = 102) or placebo (n = 34) in 1 of 5 cohorts (300, 1,000, or 3,000 mg intravenously or 100 or 300 mg intramuscularly [i.m.]) and were monitored for 360 days. The mean half-life of MEDI8897 was 85 to 117 days across dose groups, and bioavailability after 300-mg i.m. dose administration was 77%. Time to maximum concentration following i.m. dosing was 5 to 9 days. Antidrug antibody (ADA) responses were detected in a similar proportion of placebo (15.2%) and MEDI8897 (13.7%) recipients. The safety profile of MEDI8897 was similar to that of the placebo. These results support clinical studies of the i.m. administration of a single dose of MEDI8897 in the target population of infants to provide protection for the duration of the RSV season. (This study has been registered at ClinicalTrials.gov under identifier NCT02114268.).

Keywords: MEDI8897; RSV; healthy adults; infants; lower respiratory tract infections; pharmacokinetics; respiratory syncytial virus.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Subject disposition.
FIG 2
FIG 2
Mean serum MEDI8897 concentrations after a single i.v. or i.m. dose. Data have been jittered. Error bars represent the standard deviations.
FIG 3
FIG 3
Anti-RSV neutralizing antibody titers after a single i.v. or i.m. dose of MEDI8897 or placebo. Data points represent the mean anti-RSV A2 neutralizing antibody titers on a log2 scale. Data have been jittered. Error bars represent the standard deviations. Ab, antibody.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brandt CD, Kim HW, Arrobio JO, Jeffries BC, Wood SC, Chanock RM, Parrott RH. 1973. Epidemiology of respiratory syncytial virus infection in Washington, DC 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 98:355–364. - PubMed
    1. Glezen P, Denny FW. 1973. Epidemiology of acute lower respiratory disease in children. N Engl J Med 288:498–505. doi:10.1056/NEJM197303082881005. - DOI - PubMed
    1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598. doi:10.1056/NEJMoa0804877. - DOI - PMC - PubMed
    1. Hall CB. 2012. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets 12:92–97. doi:10.2174/187152612800100099. - DOI - PubMed
    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555. doi:10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data

-